×
About 6,705 results

ALLMedicine™ Cutaneous Melanoma Center

Research & Reviews  2,235 results

A Necroptosis-Related Gene Signature to Predict the Prognosis of Skin Cutaneous Melanoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683951
Disease Markers; Xie Y, Xu Z et. al.

Nov 29th, 2022 - The prognosis of skin cutaneous melanoma (SKCM) remains poor, and patients with SKCM show a poor response to immunotherapy. Thus, we aimed to identify necroptosis-related biomarkers, which can help predict the prognosis of SKCM and improve the eff...

Cost evaluation of the Merlin assay for predicting melanoma sentinel lymph node biopsy ...
https://doi.org/10.1111/ijd.16515
International Journal of Dermatology; Thao V, Dholakia R et. al.

Nov 29th, 2022 - The Merlin assay for melanoma-risk assessment has become commercially available to reduce the rate of unnecessary sentinel lymph node biopsies (SLNB) in SLNB-eligible patients with cutaneous melanoma. Merlin low-risk patients are recommended to un...

Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients...
https://doi.org/10.1016/j.jaad.2022.11.033
Journal of the American Academy of Dermatology; Sharon CE, Straker RJ et. al.

Nov 29th, 2022 - Given the results of the recent KEYNOTE-716 trial, the performance of sentinel lymph node (SLN) biopsy for patients with clinical stage IIB/C melanoma has been questioned. Determine the utility of SLN status in guiding the recommendations for adju...

A single-cell analysis reveals tumor heterogeneity and immune environment of acral mela...
https://doi.org/10.1038/s41467-022-34877-3
Nature Communications; Zhang C, Shen H et. al.

Nov 27th, 2022 - Acral melanoma is a dismal subtype of melanoma occurring in glabrous acral skin, and has a higher incidence in East Asians. We perform single-cell RNA sequencing for 63,394 cells obtained from 5 acral and 3 cutaneous melanoma samples to investigat...

An Epidemiological Update on Indoor Tanning and the Risk of Skin Cancers.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689757
Current Oncology (Toronto, Ont.); Dessinioti C, Stratigos AJ

Nov 25th, 2022 - Indoor tanning (sunbeds, solarium) uses artificial ultraviolet radiation (UVR) to stimulate cosmetic tanning of the skin. Indoor tanning has been officially classified as a human carcinogen in 2009 by the International Agency for Research on Cance...

see more →

Guidelines  9 results

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - ...
https://doi.org/10.1016/j.ejca.2022.04.018
European Journal of Cancer (Oxford, England : 1990); Garbe C, Amaral T et. al.

May 28th, 2022 - A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recomm...

SEOM clinical guideline for the management of cutaneous melanoma (2020).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057998
Clinical & Translational Oncology : Official Publication ... Majem M, Manzano JL et. al.

Mar 3rd, 2021 - Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of t...

Systemic Therapy for Melanoma: ASCO Guideline.
https://doi.org/10.1200/JCO.20.00198
Journal of Clinical Oncology : Official Journal of the Am... Seth R, Messersmith H et. al.

Apr 2nd, 2020 - To provide guidance to clinicians regarding the use of systemic therapy for melanoma. ASCO convened an Expert Panel and conducted a systematic review of the literature. A systematic review, one meta-analysis, and 34 additional randomized trials we...

Guidelines of care for the management of primary cutaneous melanoma.
https://doi.org/10.1016/j.jaad.2018.08.055
Journal of the American Academy of Dermatology; Swetter SM, Tsao H et. al.

Nov 6th, 2018 - The incidence of primary cutaneous melanoma continues to increase each year. Melanoma accounts for the majority of skin cancer-related deaths, but treatment is usually curative following early detection of disease. In this American Academy of Derm...

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immun...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977556
Journal for Immunotherapy of Cancer; Sullivan RJ, Atkins MB et. al.

Jun 1st, 2018 - Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patien...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  136 results

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Metastatic Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04157517

Oct 14th, 2022 - The drug being tested in this study is called modakafusp alfa (TAK-573). Modakafusp alfa is being tested to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor activity as single agent (SA) or in combination w...

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
https://clinicaltrials.gov/ct2/show/NCT04940299

Oct 13th, 2022 - PRIMARY OBJECTIVES: I. To characterize the safety and tolerability of systemic tocilizumab, an IL-6 receptor antagonist, in combination with Ipilimumab and nivolumab as front-line treatment for patients with advanced cutaneous melanoma, urothelial...

Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors
https://clinicaltrials.gov/ct2/show/NCT04253080

Oct 13th, 2022 - The incidence of cutaneous melanoma is increasing, but the current prognostic parameters mainly based on histological data are insufficient to identify patients with high risk of recidive. In addition, current immunotherapies using PD-1 and/or CTL...

A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (ANV419-101).
https://clinicaltrials.gov/ct2/show/NCT05578872

Oct 13th, 2022 - The purpose of this multi-site, open-label, randomized, parallel arm, Phase 1/2 adaptive study is to evaluate the efficacy and safety of ANV419 as a monotherapy and in combination with anti-PD1 antibody or anti-CTLA4 antibody in patients aged 18 y...

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
https://clinicaltrials.gov/ct2/show/NCT00145158

Oct 10th, 2022 - Patients received six sequential immunizations with 8 peptides presented by HLA-A2 and mixed with either CpG 7909 or Montanide ISA51, at 2-week intervals. The 8 peptides were injected at 8 distinct injection sites. These peptides are the following...

see more →

News  301 results

Head-to-Toe Skin Cancer Exam in Primary Care Does More Harm Than Good
https://www.medscape.com/viewarticle/983958

Nov 17th, 2022 - Kenneth W. Lin, MD, MPH Hi, everyone. I'm Dr Kenny Lin. I am a family physician and associate director of  the Lancaster General Hospital Family Medicine Residency, and I blog at Common Sense Family Doctor. A significant portion of my practice con...

Multidisciplinary Discussions Shape Systemic and Surgical Skin Cancer Treatment
https://www.onclive.com/view/multidisciplinary-discussions-shape-systemic-and-surgical-skin-cancer-treatment

Nov 15th, 2022 - Future advances in melanoma and other skin cancers should focus on team-oriented care and increasingly informed treatment sequencing regarding the roles of immunotherapy, targeted therapy, and surgery, according to Carlo Contreras, MD, who emphasi...

Dr. Carvajal on Unique Prognostic Factors in Uveal Melanoma
https://www.onclive.com/view/dr-carvajal-on-unique-prognostic-factors-in-uveal-melanoma

Nov 11th, 2022 - Richard D. Carvajal, MD, director, Experimental Therapeutics, director, the Melanoma Service, Columbia University Medical Center, discusses the prognostic factors of uveal melanoma that differentiate it from other subsets of melanoma. Uveal melan...

IMC-F106C Shows Potential as T-cell Receptor–Driven Therapy in Melanoma
https://www.onclive.com/view/imc-f106c-shows-potential-as-t-cell-receptor-driven-therapy-in-melanoma

Oct 27th, 2022 - Results from a first-in-humanphase 1 trial (NCT04262466) evaluating the efficacy and safety of IMC-F106C in patients with PRAME-positive metastatic/unresectable tumors showed a significant clinical benefit with the first PRAME×CD3 ImmTAC therapy, ...

Adjuvant Nivolumab Reduces Risk of Recurrence or Death by 58% in Select Stage IIB or IIC Melanoma
https://www.onclive.com/view/adjuvant-nivolumab-reduces-risk-of-recurrence-or-death-by-58-in-select-stage-iib-or-iic-melanoma

Oct 20th, 2022 - Adjuvant treatment with nivolumab (Opdivo) resulted in a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) over placebo in patients with completely resected stage IIB or IIC melanoma, meeting the pri...

see more →